Amivantamab concentrate for infusion | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Rybrevant
- Company
- Janssen-Cilag International NV (EU authorization holder)
- Medicine type
- Biologic
- Therapeutic area
- Oncology
- Indications recorded in the public source
- EU: Adults with advanced non-small cell lung cancer with activating EGFR exon 20 insertions: first line with carboplatin and pemetrexed, or alone after platinum-based therapy fails. For EGFR exon 19 deletions or exon 21 L858R mutations: first line with lazertinib, or with carboplatin and pemetrexed after prior therapy including an EGFR tyrosine kinase inhibitor fails.
- Indication source and scope
- English EMA EPAR overview and product details accessed 2026-11-02. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Regulatory product information / approval evidence is linked; a complete current prescribing-information document has not been verified in this review.
- China availability status
- Chinese approval, locally approved indications and current availability have not been independently verified in this import.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant
- Rybrevant — EMA medicine overview and product details
Regulatory medicine overview · English EMA EPAR overview and product details accessed 2026-11-02
English primary source reviewed. This evidence describes the cited overseas jurisdiction and does not verify Chinese approval, indications, reimbursement or market availability.
- HPRA Rybrevant authorization record
Regulatory authorization record · Accessed 2026-11-02
Confirms the EU authorization holder; the linked record is a subcutaneous presentation, while the indications and IV formulation above come from EMA overview.
Evidence reviewed:
Open the interactive record, public price references and discussions